Stoke Therapeutics Inc Market Cap ($1.70 Billion)
Market Cap & Net Worth: Stoke Therapeutics Inc (STOK)
Stoke Therapeutics Inc market cap. Stoke Therapeutics Inc (NASDAQ:STOK) has a market capitalization of $1.70 Billion ($1.70 Billion) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6470 globally and #2070 in its home market, demonstrating a 2.30% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Stoke Therapeutics Inc's stock price $26.29 by its total outstanding shares 64526242 (64.53 Million). Also see Stoke Therapeutics Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Stoke Therapeutics Inc Market Cap History (2019–2026)
Stoke Therapeutics Inc market cap history from 2019 to 2026. Data shows growth from $1.83 Billion to $1.70 Billion (0.38% CAGR). Check STOK share price today for real-time trading data and today's change.
Index Memberships
Stoke Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.06% | #186 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.00% | #731 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.09% | #111 of 263 |
Weight: Stoke Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Stoke Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Stoke Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore STOK year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
11.11x
Stoke Therapeutics Inc's market cap is 11.11 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.55 Billion | $3.00 Million | -$84.71 Million | 515.99x | N/A |
| 2022 | $595.58 Million | $12.40 Million | -$93.11 Million | 48.01x | N/A |
| 2023 | $339.41 Million | $8.78 Million | -$104.70 Million | 38.66x | N/A |
| 2024 | $711.72 Million | $36.55 Million | -$88.98 Million | 19.47x | N/A |
| 2025 | $2.05 Billion | $184.42 Million | -$6.88 Million | 11.11x | N/A |
Competitor Companies of STOK by Market Capitalization
Companies near Stoke Therapeutics Inc in the global market cap rankings as of November 1, 2026. Also see Stoke Therapeutics Inc total assets for a full breakdown of the balance sheet.
Key companies related to Stoke Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Stoke Therapeutics Inc (2019–2026)
Market capitalization of Stoke Therapeutics Inc from 2019 to today. Between 2019 and today, Stoke Therapeutics Inc's market cap moved from $1.83 Billion to $ 1.70 Billion, with a yearly change of 0.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.70 Billion | -17.17% |
| 2025 | $2.05 Billion | +187.76% |
| 2024 | $711.72 Million | +109.70% |
| 2023 | $339.41 Million | -43.01% |
| 2022 | $595.58 Million | -61.53% |
| 2021 | $1.55 Billion | -61.26% |
| 2020 | $4.00 Billion | +118.68% |
| 2019 | $1.83 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Stoke Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.70 Billion USD |
| MoneyControl | $1.70 Billion USD |
| MarketWatch | $1.70 Billion USD |
| marketcap.company | $1.70 Billion USD |
| Reuters | $1.70 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Stoke Therapeutics Inc
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials fo… Read more